Palmitate and insulin synergistically induce IL-6 expression in human monocytes

Cardiovascular Diabetology

Volumn 9, Issue , 2010, Pages

  Bunn, Robert C ^a   Cockrell, Gael E ^a   Ou, Yang ^a   Thrailkill, Kathryn M ^a   Lumpkin Jr, Charles K ^a   Fowlkes, John L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE; COENZYME A; FATTY ACID; GLYCEROLIPID; INSULIN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PALMITIC ACID; PROTEIN KINASE B; SATURATED FATTY ACID; TUMOR NECROSIS FACTOR ALPHA; AUTACOID; IL6 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; ATHEROSCLEROSIS; BIOASSAY; BIOSYNTHESIS; CHRONIC DISEASE; COENZYME; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; ESTERIFICATION; FATTY ACID OXIDATION; HUMAN; HUMAN CELL; HYPERINSULINEMIA; INCUBATION TEMPERATURE; INFLAMMATION; INSULIN RESISTANCE; LIPOGENESIS; MONOCYTE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STUDENT T TEST; TUMOR NECROSIS; WESTERN BLOTTING; GENETICS; IMMUNOLOGY; METABOLISM; OXIDATION REDUCTION REACTION; PHOSPHORYLATION; TUMOR CELL LINE; UPREGULATION;

CELL LINE, TUMOR; CERAMIDES; COENZYME A; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FATTY ACIDS, NONESTERIFIED; HUMANS; INFLAMMATION MEDIATORS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; MAP KINASE KINASE KINASES; MONOCYTES; OXIDATION-REDUCTION; PALMITIC ACID; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 78049408569     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-9-73     Document Type: Article

References (51)

1. Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995, 75:473-486.
2. Razani B, Chakravarthy MV, Semenkovich CF. Insulin resistance and atherosclerosis. Endocrinol Metab Clin North Am 2008, 37:603-621. viii, 10.1016/j.ecl.2008.05.001, 2639785, 18775354.
3. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology 2007, 132:2169-2180. 10.1053/j.gastro.2007.03.059, 17498510.
4. Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 2000, 148:209-214. 10.1016/S0021-9150(99)00463-3, 10657556.
5. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91. 10.1126/science.7678183, 7678183.
6. Kern PA, Saghizadeh M, Ong JM, Bosch RJ, Deem R, Simsolo RB. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995, 95:2111-2119. 10.1172/JCI117899, 295809, 7738178.
7. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997, 82:4196-4200. 10.1210/jc.82.12.4196, 9398739.
8. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808. 296995, 14679176.
9. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001, 280:E745-751.
10. Auffray C, Sieweke MH, Geissmann F. Blood monocytes: development, heterogeneity, and relationship with dendritic cells. Annu Rev Immunol 2009, 27:669-692. 10.1146/annurev.immunol.021908.132557, 19132917.
11. Grage-Griebenow E, Flad HD, Ernst M. Heterogeneity of human peripheral blood monocyte subsets. J Leukoc Biol 2001, 69:11-20.
12. Swirski FK, Weissleder R, Pittet MJ. Heterogeneous in vivo behavior of monocyte subsets in atherosclerosis. Arterioscler Thromb Vasc Biol 2009, 29:1424-1432. 10.1161/ATVBAHA.108.180521, 2746262, 19372462.
13. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005, 5:953-964. 10.1038/nri1733, 16322748.
14. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007, 117:175-184. 10.1172/JCI29881, 1716210, 17200717.
15. Swirski FK, Libby P, Aikawa E, Alcaide P, Luscinskas FW, Weissleder R, Pittet MJ. Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007, 117:195-205. 10.1172/JCI29950, 1716211, 17200719.
16. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004, 110:1564-1571. 10.1161/01.CIR.0000142055.53122.FA, 15364812.
17. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A, Dandona P. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003, 52:2882-2887. 10.2337/diabetes.52.12.2882, 14633847.
18. Bouhlel MA, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx N, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007, 6:137-143. 10.1016/j.cmet.2007.06.010, 17681149.
19. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 2006, 116:3015-3025. 10.1172/JCI28898, 1616196, 17053832.
20. Heil TL, Volkmann KR, Wataha JC, Lockwood PE. Human peripheral blood monocytes versus THP-1 monocytes for in vitro biocompatibility testing of dental material components. J Oral Rehabil 2002, 29:401-407. 10.1046/j.1365-2842.2002.00893.x, 12028485.
21. Devaraj S, Venugopal SK, Singh U, Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes 2005, 54:85-91. 10.2337/diabetes.54.1.85, 15616014.
22. Boden G. Fatty acid-induced inflammation and insulin resistance in skeletal muscle and liver. Curr Diab Rep 2006, 6:177-181. 10.1007/s11892-006-0031-x, 16898568.
23. Oakes ND, Thalen P, Aasum E, Edgley A, Larsen T, Furler SM, Ljung B, Severson D. Cardiac metabolism in mice: tracer method developments and in vivo application revealing profound metabolic inflexibility in diabetes. Am J Physiol Endocrinol Metab 2006, 290:E870-881. 10.1152/ajpendo.00233.2005, 16352676.
24. Oakes ND, Kjellstedt A, Forsberg GB, Clementz T, Camejo G, Furler SM, Kraegen EW, Olwegard-Halvarsson M, Jenkins AB, Ljung B. Development and initial evaluation of a novel method for assessing tissue-specific plasma free fatty acid utilization in vivo using (R)-2-bromopalmitate tracer. J Lipid Res 1999, 40:1155-1169.
25. Gill JM, Sattar N. Ceramides: A new player in the inflammation-insulin resistance paradigm?. Diabetologia 2009, 52:2475-2477. 10.1007/s00125-009-1546-x, 19802602.
26. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806. 10.1038/414799a, 11742412.
27. Staiger H, Staiger K, Stefan N, Wahl HG, Machicao F, Kellerer M, Haring HU. Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes 2004, 53:3209-3216. 10.2337/diabetes.53.12.3209, 15561952.
28. Ajuwon KM, Spurlock ME. Palmitate activates the NF-kappaB transcription factor and induces IL-6 and TNFalpha expression in 3T3-L1 adipocytes. J Nutr 2005, 135:1841-1846.
29. Weigert C, Brodbeck K, Staiger H, Kausch C, Machicao F, Haring HU, Schleicher ED. Palmitate, but not unsaturated fatty acids, induces the expression of interleukin-6 in human myotubes through proteasome-dependent activation of nuclear factor-kappaB. J Biol Chem 2004, 279:23942-23952. 10.1074/jbc.M312692200, 15028733.
30. Laine PS, Schwartz EA, Wang Y, Zhang WY, Karnik SK, Musi N, Reaven PD. Palmitic acid induces IP-10 expression in human macrophages via NF-kappaB activation. Biochem Biophys Res Commun 2007, 358:150-155. 10.1016/j.bbrc.2007.04.092, 17467667.
31. Lee JY, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 2001, 276:16683-16689. 10.1074/jbc.M011695200, 11278967.
32. Zhang WY, Schwartz E, Wang Y, Attrep J, Li Z, Reaven P. Elevated concentrations of nonesterified fatty acids increase monocyte expression of CD11b and adhesion to endothelial cells. Arterioscler Thromb Vasc Biol 2006, 26:514-519. 10.1161/01.ATV.0000200226.53994.09, 16357311.
33. Senn JJ. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 2006, 281:26865-26875. 10.1074/jbc.M513304200, 16798732.
34. Coleman RA, Lewin TM, Muoio DM. Physiological and nutritional regulation of enzymes of triacylglycerol synthesis. Annu Rev Nutr 2000, 20:77-103. 10.1146/annurev.nutr.20.1.77, 10940327.
35. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008, 118:2992-3002. 10.1172/JCI34260, 2522344, 18769626.
36. Schwartz EA, Zhang WY, Karnik SK, Borwege S, Anand VR, Laine PS, Su Y, Reaven PD. Nutrient Modification of the Innate Immune Response. A Novel Mechanism by Which Saturated Fatty Acids Greatly Amplify Monocyte Inflammation. Arterioscler Thromb Vasc Biol 2010, 30:802-808. 10.1161/ATVBAHA.109.201681, 20110572.
37. Tataranni PA, Ortega E. A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?. Diabetes 2005, 54:917-927. 10.2337/diabetes.54.4.917, 15793228.
38. Fisman EZ, Adler Y, Tenenbaum A. Biomarkers in cardiovascular diabetology: interleukins and matrixins. Adv Cardiol 2008, 45:44-64. full_text, 18230955.
39. Fisman EZ, Tenenbaum A. The ubiquitous interleukin-6: a time for reappraisal. Cardiovasc Diabetol 2010, 9:62. 10.1186/1475-2840-9-62, 2959009, 20937099.
40. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 2003, 52:812-817. 10.2337/diabetes.52.3.812, 12606524.
41. Bermudez LE, Wu M, Petrofsky M, Young LS. Interleukin-6 antagonizes tumor necrosis factor-mediated mycobacteriostatic and mycobactericidal activities in macrophages. Infect Immun 1992, 60:4245-4252. 257459, 1328056.
42. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, et al. Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 2006, 55:2688-2697. 10.2337/db05-1404, 17003332.
43. Ruderman NB, Keller C, Richard AM, Saha AK, Luo Z, Xiang X, Giralt M, Ritov VB, Menshikova EV, Kelley DE, et al. Interleukin-6 regulation of AMP-activated protein kinase. Potential role in the systemic response to exercise and prevention of the metabolic syndrome. Diabetes 2006, 55(Suppl 2):S48-54. 10.2337/db06-S007, 17130644.
44. Matthews VB, Allen TL, Risis S, Chan MH, Henstridge DC, Watson N, Zaffino LA, Babb JR, Boon J, Meikle PJ, et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010, 53:2431-2441. 10.1007/s00125-010-1865-y, 20697689.
45. Baumgartl J, Baudler S, Scherner M, Babaev V, Makowski L, Suttles J, McDuffie M, Tobe K, Kadowaki T, Fazio S, et al. Myeloid lineage cell-restricted insulin resistance protects apolipoproteinE-deficient mice against atherosclerosis. Cell Metab 2006, 3:247-256. 10.1016/j.cmet.2006.02.010, 16581002.
46. Mauer J, Chaurasia B, Plum L, Quast T, Hampel B, Bluher M, Kolanus W, Kahn CR, Bruning JC. Myeloid cell-restricted insulin receptor deficiency protects against obesity-induced inflammation and systemic insulin resistance. PLoS Genet 2010, 6:e1000938. 10.1371/journal.pgen.1000938, 2865520, 20463885.
47. Schillaci R, Eugui EM, Roldan A. Insulin effect on interleukin 1 (IL-1) and interleukin 6 (IL-6) production by lipopolysaccharide-stimulated human monocytes. Horm Metab Res 1994, 26:113-115. 10.1055/s-2007-1000785, 8200613.
48. Cusi K, Maezono K, Osman A, Pendergrass M, Patti ME, Pratipanawatr T, DeFronzo RA, Kahn CR, Mandarino LJ. Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000, 105:311-320. 10.1172/JCI7535, 377440, 10675357.
49. Jiang ZY, Lin YW, Clemont A, Feener EP, Hein KD, Igarashi M, Yamauchi T, White MF, King GL. Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999, 104:447-457. 10.1172/JCI5971, 408521, 10449437.
50. Lagrand WK, Visser CA, Hermens WT, Niessen HW, Verheugt FW, Wolbink GJ, Hack CE. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 1999, 100:96-102.
51. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U. Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 2000, 20:2019-2023.